wsj.com To view or add a comment, sign in The GLP-1 market is projected to hit $130 billion globally by 2030
These formulations are not mass-produced pharmaceutical products and are not individually approved by the FDA in the same way as branded drugs
Wyckoff JA, Lapolla A, Asias-Dinh BD, Barbour LA, Brown FM, Catalano PM, et al
Pros: Low cost Multiple size options Contains some additional vitamins Cons: Questionable sourcing No purity testing Contains unnecessary additives 10
It's the kind of ingredient list that makes you think you're in for a fantastic brightening, barrier-supporting product
"Glutathione levels in human tumors"